GE HealthCare Technologies Inc. GEHC

GE HealthCare’s strongest sourced fact today is the first quarter 2026 filing package: the 2026-04-29 8-K says the company issued a press release announcing first quarter 2026 financial results, and the 10-Q for the period ended 2026-03-31 gives the hard figures behind the story.

The company describes itself in the 10-Q as a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions. The official issuer rail adds that GE HealthCare has released its 2025 sustainability report, says it has over 130 years of delivering healthcare solutions, and says it tops the FDA’s list of AI-enabled medical devices. Those claims identify the operating field; they do not, by themselves, prove a new launch or a new sales inflection.

The latest SEC EDGAR financials show revenue from contract with customer, excluding assessed tax, of $5.13B, operating income of $515.0M, net income attributable to parent of $389.0M, and diluted EPS of $0.85 for the 10-Q period ending 2026-03-31. The same filing shows assets of $37.12B, liabilities of $26.23B, stockholders' equity attributable to parent of $10.67B, cash and cash equivalents of $2.26B, and net cash provided by operating activities of $290.0M.

The supplied source rail does not include a chart route, live price series, candle data or TradingView context, so this file cannot describe levels, volume behaviour or technical momentum. The market mechanism available here is the public filing trail: a 10-Q, an 8-K announcing first quarter results, the SEC submissions JSON, the companyfacts JSON, Form 4 filings, Schedule 13G/A filings and the 2026-05-29 Form SD.

What changed in the provided public record is concentrated in late April and May 2026. GEHC filed the first quarter 2026 8-K and 10-Q on 2026-04-29, followed by a 2026-05-11 8-K, two Schedule 13G/A filings dated 2026-05-14, Form 4 filings dated 2026-05-19 and 2026-05-26, and a Form SD dated 2026-05-29. The rail names those events but does not provide transaction-level Form 4 details, ownership percentages from the 13G/A filings, or Form SD contents beyond the filing event.

The operating tension is clear enough without importing outside colour. GE HealthCare is funding product and technology work, with $345.0M of research and development expense in the latest 10-Q, while carrying $2.35B of inventory, a $171.0M increase in inventories, and $43.0M of warranty accrual for warranties issued. For a healthcare technology equity, that is the practical bridge between product ambition and cash discipline.